| Genotype 3 SVR, % (95% CI) | Genotype 3a SVR, % (95% CI) | Genotype 3b SVR, % (95% CI) | ||||||
---|---|---|---|---|---|---|---|---|---|
All patients | All patients | LDV/SOF | DAC + SOF | SOF/VEL | All patients | LDV/SOF | DAC + SOF | SOF/VEL | |
Patients who complete, N | 303 | 216 | 7 | 186 | 23 | 28 | NA | 27 | 1 |
 All durations | 96.7 (94.0–98.2) | 97.2 (94.1–98.7) | 85.7 (48.7–97.4) | 98.4 (95.4–99.5) | 91.3 (73.2–97.6) | 89.3 (72.8–96.3) | NA | 88.9 (71.9–96.1) | 100 (20.7–100) |
 12-wk treatment | 96.3 (92.8–98.1) | 96.9 (92.9–98.6) | 80.0 (37.6–96.4) | 98.5 (94.6–99.6) | 91.3 (73.2–97.6) | 88.9 (67.2–96.9) | NA | 88.2 (65.7–96.7) | 100 (20.7–100) |
 16-wk treatment | 93.5 (79.3–98.2) | 93.8 (71.7–98.9) | NA | 93.8 (71.7–98.9) | NA | 83.3 (43.6–97.0) | NA | 83.3 (43.6–97.0) | NA |
 24-wk treatment | 100 (93.8–100) | 100 (91.4–100) | 100 (34.2–100) | 100 (91.0–100) | NA | 100 (51.0–100) | NA | 100 (51.9–100) | NA |
SVR in the following subgroups | |||||||||
 No cirrhosis | 99.0 (94.8–99.8) | 100 (95.1–100) | 100 (34.2–100) | 100 (94.6–100) | 100 (61.0–100) | 90.9 (62.3–98.4) | NA | 90.9 (62.3–98.4) | NA |
 Cirrhosis | 95.5 (91.6–97.6) | 95.7 (91.0–98.0) | 80.0 (37.6–96.4) | 97.5 (92.8–99.1) | 88.2 (65.7–96.7) | 88.2 (65.7–96.7) | NA | 87.5 (64.0–96.5) | 100 (20.7–100) |
 Decompensated cirrhosis | 88.4 (75.5–94.9) | 86.7 (70.3–94.7) | 100 (20.7–100) | 91.7 (74.2–97.7) | 80.0 (37.6–96.4) | 100 (61.0–100) | NA | 100 (61.0–100) | NA |
 Treatment-naive | 96.8 (92.7–98.6) | 95.5 (89.8–98.0) | 66.7 (20.8–93.9) | 96.6 (90.6–98.8) | 94.4 (74.2–99.0) | 100 (84.5–100) | NA | 100 (84.5–100) | NA |
 Treatment-experienced | 96.6 (92.3–98.5) | 99.1 (94.8–99.8) | 100 (51.0–100) | 100 (96.2–100) | 80.0 (37.6–96.4) | 57.1 (25.0–84.2) | NA | 50.0 (18.8–81.2) | 100 (20.7–100) |